Last reviewed · How we verify

DTaP-HB PRP~T Combined Vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-HB PRP~T Combined Vaccine is a Vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) by presenting inactivated toxins and bacterial antigens.

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) by presenting inactivated toxins and bacterial antigens. Used for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-HB PRP~T Combined Vaccine
SponsorSanofi Pasteur, a Sanofi Company
Drug classVaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

DTaP-HB-PRP~T is a pentavalent vaccine combining five separate immunizations into one injection. It contains inactivated diphtheria and tetanus toxoids, acellular pertussis antigens, hepatitis B surface antigen (produced via recombinant DNA), and polyribosylribitol phosphate (PRP) from Hib conjugated to tetanus toxoid. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, conferring protection against these five serious bacterial and viral diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-HB PRP~T Combined Vaccine

What is DTaP-HB PRP~T Combined Vaccine?

DTaP-HB PRP~T Combined Vaccine is a Vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

How does DTaP-HB PRP~T Combined Vaccine work?

This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b (Hib) by presenting inactivated toxins and bacterial antigens.

What is DTaP-HB PRP~T Combined Vaccine used for?

DTaP-HB PRP~T Combined Vaccine is indicated for Active immunization against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-HB PRP~T Combined Vaccine?

DTaP-HB PRP~T Combined Vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

What drug class is DTaP-HB PRP~T Combined Vaccine in?

DTaP-HB PRP~T Combined Vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is DTaP-HB PRP~T Combined Vaccine in?

DTaP-HB PRP~T Combined Vaccine is in Phase 3.

What are the side effects of DTaP-HB PRP~T Combined Vaccine?

Common side effects of DTaP-HB PRP~T Combined Vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related